FLT3LG and breast neoplasm: To determine the optimal Flt3L regimen resulting in the highest numbers of cDCs in orthotopic E0771 breast tumors, 30 μg Flt3L or vehicle was administered daily for 6, 9 or 12 days before sacrifice (Figure S1A).